Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 2/20 | 0.48 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.48 |
| ▸ | MMP2 | P08253 | 7/20 | 0.47 |
| ▸ | CA12 | O43570 | 5/20 | 0.47 |
| ▸ | CA1 | P00915 | 5/20 | 0.47 |
| ▸ | CA2 | P00918 | 5/20 | 0.47 |
| ▸ | CA9 | Q16790 | 5/20 | 0.47 |
| ▸ | MMP1 | P03956 | 2/20 | 0.47 |
| ▸ | MMP8 | P22894 | 2/20 | 0.47 |
| ▸ | MMP3 | P08254 | 1/20 | 0.47 |
| ▸ | FDPS | P14324 | 3/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (Cyclooctylamino)Methylenediphosphonic Acid SCHEMBL9777403 | 1.00 | ANPEP (0.48) | ANPEPERAP2MMP2CA12CA1 | |
| Incadronic Acid SCHEMBL223885 | 1.00 | ANPEP (0.48) | ANPEPERAP2MMP2CA12CA1 | |
| (Cyclopentylamino)Methylenediphosphonic Acid SCHEMBL9626232 | 0.98 | ANPEP (0.46) | ANPEPERAP2MMP2CA12CA1 | |
| Incadronic Acid SCHEMBL2898450 | 0.96 | ANPEP (0.46) | ANPEPERAP2MMP2CA12CA1 | |
| (Cyclobutylamino)Methylenediphosphonic Acid SCHEMBL9626988 | 0.93 | MMP2 (0.45) | ANPEPERAP2MMP2CA12CA1 | |
| (Cyclopropylamino)Methylenediphosphonic Acid SCHEMBL9627717 | 0.88 | MMP2 (0.41) | ANPEPERAP2MMP2CA12CA1 | |
| Incadronic Acid SCHEMBL2898447 | 0.85 | ANPEP (0.41) | ANPEPERAP2MMP2CA12CA1 | |
| Incadronic Acid SCHEMBL29355743 | 0.81 | MMP2 (0.42) | ANPEPERAP2MMP2CA12CA1 | |
| SCHEMBL18657116 | 0.80 | ANPEP (0.47) | ANPEPERAP2MMP2CA12CA1 | |
| SCHEMBL10419330 | 0.78 | HDAC3 (0.33) | ANPEPERAP2MMP2MMP1MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023107893-A2 | TREATMENT OF NEUORODEGENERATIVE DISEASES THROUGH THE INHIBITION OF ATAXIN-2 | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-06-15 | — | — | WO | claimed |
| EP-0566535-B1 | Compositions comprising methanediphosphonic acids and ion-exchangers | NOVARTIS AG (CH) | 1999-08-11 | — | — | EP | claimed |
| US-5344825-A | Cationic divinylbenzene-styrene copolymer with exchangeable phosphonic acid methylaminomethyl groups and sodium salts | CIBA-GEIGY CORP. (US) | 1994-09-06 | — | — | US | claimed |
| EP-0566535-A1 | Compositions comprising methanediphosphonic acids and ion-exchangers | CIBA-GEIGY AG (CH) | 1993-10-20 | — | — | EP | claimed |
| US-RE50880-E1 | Anti-human OX40L antibodies and methods of treatment | KYMAB LIMITED (GB) | 2026-05-05 | — | — | US | disclosed |
| US-20250263492-A1 | ANTIBODIES, USES & METHODS | KYMAB LTD (GB) | 2025-08-21 | — | — | US | disclosed |
| EP-4562053-A1 | ANTI-KIT ANTIBODY FORMULATIONS AND METHODS | Celldex Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| WO-2025106361-A1 | HUMAN NECTIN-4 BINDERS | MERCK SHARP & DOHME LLC (US) | 2025-05-22 | — | — | WO | disclosed |
| CN-119948056-A | Anti-KIT antibody formulations and methods | 塞尔德克斯医疗公司 | 2025-05-06 | — | — | CN | disclosed |
| US-20250129159-A1 | METHODS OF TREATING CANCER USING ANTIBODIES AND MOLECULES THAT IMMUNOSPECIFICALLY BIND TO BTN1A1 | STCUBE & CO INC (KR) | 2025-04-24 | — | — | US | disclosed |
| US-20250052758-A1 | RECEPTOR FOR VISTA | PIERRE FABRE MEDICAMENT (FR) | 2025-02-13 | — | — | US | disclosed |
| US-12215151-B2 | Methods of treating cancer using antibodies and molecules that immunospecifically bind to BTN1A1 | STCUBE & CO., INC. (KR) | 2025-02-04 | — | — | US | disclosed |
| EP-0566535-B1 | Compositions comprising methanediphosphonic acids and ion-exchangers | NOVARTIS AG (CH) | 1999-08-11 | — | — | EP | disclosed |
| US-5344825-A | Cationic divinylbenzene-styrene copolymer with exchangeable phosphonic acid methylaminomethyl groups and sodium salts | CIBA-GEIGY CORP. (US) | 1994-09-06 | — | — | US | disclosed |
| EP-0566535-A1 | Compositions comprising methanediphosphonic acids and ion-exchangers | CIBA-GEIGY AG (CH) | 1993-10-20 | — | — | EP | disclosed |
| EP-0325482-B1 | (CYCLOALKYLAMINO)METHYLENEBISPHOSPHONIC ACIDS AND MEDICINES CONTAINING THEM | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1992-04-01 | — | — | EP | disclosed |
| US-5041428-A | Bone resorption inhibitor, antiarthritic agent | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1991-08-20 | — | — | US | disclosed |
| US-4970335-A | ANTIARTHRITIC AGENTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1990-11-13 | — | — | US | disclosed |
| US-3979385-A | HEAVY METAL COMPLEXING AGENTS | HENKEL & CIE G.M.B.H. (DT) | 1976-09-07 | — | — | US | disclosed |
| US-3957160-A | Process for the prevention of precipitations in water or aqueous solutions | HENKEL & CIE G.M.B.H. (DT) | 1976-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12215151-B2 | Methods of treating cancer using antibodies and molecules that immunospecifically bind to BTN1A1 | CD274, BTN3A1, PDCD1LG2 | ANPEP 464/4885ERAP2 3665/4885MMP2 2506/4885 |
| US-20250129159-A1 | METHODS OF TREATING CANCER USING ANTIBODIES AND MOLECULES THAT IMMUNOSPECIFICALLY BIND TO BTN1A1 | CD274, BTN3A1, PDCD1LG2 | ANPEP 464/4885ERAP2 3665/4885MMP2 2506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.